Marshall Wace is a global asset manager that offers a diverse range of investors alternative investment solutions.
Founded in 1997, Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong. Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year.The firm is dedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world.Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 9, 2015 | Private Equity(PE) | — | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 5, 2022
Karyopharm Therapeutics
|
Post-IPO Equity | $165M | Health Care | — |
Nov 9, 2022
TRM Labs
|
Series B | $70M | Big Data | — |
Sep 6, 2022
21.co
|
Series Unknown | $25M | Blockchain | Yes |
Apr 29, 2022
Turtlemint
|
Series E | $120M | Financial Services | — |
Apr 12, 2022
Circle
|
Private Equity(PE) | $400M | Banking | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kohlberg Kravis Roberts | — | Private Equity(PE) |